PBI Short Sellers Hold Ground as CEO Sells Into the Rally
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Pitney Bowes shares have gained 6% over the past month to $17.44, yet 11.4% of the free float remains sold short, one of the more crowded positions in the office services space. Short interest edged up roughly 2% over the past month, though it pulled back about 2% in the past week. The borrow market gives shorts little urgency to cover: availability is extremely loose at 567%, meaning there are nearly six shares available to borrow for every one already lent out, well above the 52-week tightest reading of 200%. Cost to borrow sits at just 0.45%, barely above flat. Options tell a mildly more cautious story, with the put/call ratio at 0.28, its highest level of the past year and about 1.2 standard deviations above its 20-day average, though the absolute level remains low enough that this looks like selective hedging rather than defensive positioning.
The more striking signal is in the insider register. CEO Kurt James Wolf has sold more than $2.4 million in stock during October alone, all under a pre-arranged 10b5-1 plan, and his 90-day net selling across the company totals roughly $32 million in value across nearly 1.8 million shares. Plan-driven sales are less of a conviction signal than discretionary trades, but the scale here is notable: Wolf also filed a Schedule 13D amendment in May after his stake fell from 5.3% to 4.6%, and he has now dropped below the 5% disclosure threshold. Per SEC rules, a holder who falls below 5% may exit without a further filing, so his current position is not publicly confirmed. This activist-to-passive transition at the CEO level is one of the most unusual features of the PBI setup heading into the print.
The analyst community has been a steady source of upward revisions across 2026. Citizens has raised its target four times this year, most recently to $22 in late July, while Truist lifted its target to $18 from $15 in early August after last quarter's results. BofA upgraded the stock from Underperform to Neutral in May, taking its target from $9.50 to $16.50. The stock at $17.44 trades above that BofA target, and the mean across analysts is $19.56. Bears focus on the structural slide in U.S. physical mail volumes, the exposure of the SendTech segment to that decline, and the risk that potential USPS privatisation or workshare discount changes could further compress revenue visibility. The bull case rests on improving operating momentum, management's guidance for $1.80 to $1.86 billion in 2026 revenue with adj. EBIT of $425 to $465 million, aggressive capital returns including $136 million in buybacks in the first quarter, and the often-overlooked Pitney Bowes Bank, which has over 400,000 customers and more than $574 million in deposits.
One further data point stands out. Retail attention, measured by Wikipedia page views against the company's own 90-day history, is running at a z-score of 2.3, the highest in the dataset for this stock. The spike coincides with today's earnings release, which is the natural explanation, though unusually elevated attention ahead of a print can amplify the price reaction in either direction.
The print will test whether the improving operational narrative management has been signalling, including narrowing SendTech declines and Presort volume recovery, is showing up in the actual numbers at a level that justifies a stock price that has already moved well past the most recently revised analyst targets from the lower-conviction names on the register.
Stocks in this article
See the live data behind this article on ORTEX.
Open PBI on ORTEX →How this article was generated
- Generated
- 29 Oct 2026, 04:30
- Data as of
- 29 Oct 2026, 04:07
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.